Patent · US Active

Pharmaceutical composition

US11291661B2 · kind B2 · utility

0Cited by

1References

20Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Geoffrey GOGNIAT · Basel, CH
Saran Kumar · Edison, US
Ulrich Meier · Wetzikon, CH
Mario RENTSCH · Basel, CH

Key dates

Filing date	Mar 11, 2020
Grant date	Apr 5, 2022
Priority date	—
Expiry date	Mar 11, 2040

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P1/16
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to the field of pharmacy, particularly to a pharmaceutical composition for oral administration comprising an (a) inert substrate and a (b) mixture comprising a non-bile acid farnesoid X receptor (FXR) agonist, such as 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder. The present invention also relates to a process for preparing said pharmaceutical composition for oral administration; and to the use of said pharmaceutical composition in the manufacture of a medicament.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.